Lineage Cell Therapeutics (LCTX) Tops Q1 EPS by 2c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q1 EPS of ($0.01), $0.02 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $391 thousand versus the consensus estimate of $350 thousand.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• CVG to join Russell 2000 and Russell 3000 indexes June 26